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Abstract
Background: This study aimed to investigate if the homocysteine-lowering efficacy of two commonly used
physiological doses (0.4 mg/d and 0.8 mg/d) of folic acid (FA) can be modified by individual
methylenetetrahydrofolate reductase (MTHFR) C677T and/or methionine synthase (MTR) A2756G polymorphisms in
hypertensive Chinese adults.
Methods: A total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three
treatment groups: 1) enalapril only (10 mg, control group); 2) enalapril-FA tablet [10:0.4 mg (10 mg enalapril combined
with 0.4 mg of FA), low FA group]; and 3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks.
Results: After 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA
dosage groups, except in subjects with MTR 2756AG /GG genotype in the low FA group at week 4. However,
compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects
with CT or TT genotype in the low FA group (P < 0.05 for either of these genotypes) and TT genotype in the high
FA group (P < 0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response
than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8:
CC 10.8% vs. TT: 22.0%, P = 0.005), but not in the low FA group (CC 9.9% vs. TT 11.2%, P = 0.989).
Conclusions: This study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine
concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of
FA supplementation.
Keywords: Folic acid supplementation, MTHFR C677T polymorphism, MTR A2756G polymorphism, Homocysteine-
lowering efficacy
Background
Traditional risk factors are estimated to account for only
part of cardiovascular disease (CVD) risk [1]. Non-tradi-
tional risk factors such as increased homocysteine concen-
trations are believed to be causally related to CVD [2].
The interactive effect between hypertension and
hyperhomocysteinemia on the risk of CVD has received
great attention [3]. Our previous meta-analysis [4] sug-
gested that folic acid (FA) supplementation could signifi-
cantly reduce the risk of stroke by 18% [Relative Risk
(RR):0.82, 95% Confidence Interval (CI): 0.68-1.00; P =
0.045), and an even greater beneficial effect was seen in
those trials with no or partial FA fortification (RR: 0.75,
95%CI: 0.62-0.91; P = 0.003). Furthermore, FA supplemen-
tation was found to significantly reduce CVD risk in
patients with end stage renal disease or advanced chronic
kidney disease (creatinine clearance < 30 mL/min) by 15%
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any medium, provided the original work is properly cited.(RR: 0.85; 95CI: 0.76-0.96, P = 0.009), particularly in trials
with no or partial FA fortification (RR: 0.80; 95% CI: 0.65-
0.99; p = 0.04) [5]. These findings underscore the impor-
tance of effectively lowering homocysteine concentration
in the prevention of CVD, particularly in populations with
a high prevalence of hypertension and hyperhomocystie-
nemia but without FA fortification.
Methylenetetrahydrofolate reductase (MTHFR) and
methionine synthase (MTR) are the main regulatory
enzymes for homocysteine metabolism. MTHFR converts
5, 10-methylene-THF into 5-methyl-THF. Polymorphism
of MTHFR C677T leads to a reduction in enzyme activity,
which may lead to an increased concentration of plasma
homocysteine and lower levels of serum folate, particularly
in those with low folate intake [6]. MTR catalyzes the
demethylation of 5-methyl-THF to THF and the remethy-
lation (using the methyl group donated by 5-methyl-THF)
of homocysteine to methionine. A common polymorph-
ism in the MTR gene (A2756G) also seems to influence
plasma homocysteine [7].
To our knowledge, no published trial has investigated if
the homocysteine-lowering efficacy of two commonly
used doses (0.4 mg/d and 0.8 mg/d) of FA can be modified
by individual MTHFR C677T and MTG A2756G poly-
morphisms in hypertensive adults without FA fortification.
In this report, we analyzed the data from a randomized,
double-blind, controlled trial that included three interven-
tion groups: 1) enalapril only (10 mg, control group); 2)
enalapril-FA tablet (10 mg enalapril combined with 0.4 mg
of FA, low FA group); and 3) enalapril-FA tablet (10 mg
enalapril combined with 0.8 mg of FA, high FA group),
once daily for 8 weeks. We sought to assess if MTHFR or
MTR genotypes can influence a change in plasma homo-
cysteine concentration in response to each of the two dif-
ferent dosages of FA supplementation.
Methods
This was a multicenter, randomized, double-blind con-
trolled trial in hypertensive Chinese adults (clinicaltrials.
gov; identifier: NCT00520247) [8]. The details regarding
“Subjects”, “Intervention and data collection”, “Laboratory
methods”,a n d“Statistical Analysis” have been previously
described [9]. Briefly, 480 patients with mild or moderate
hypertension were recruited from six hospitals in different
Chinese regions (Ha’erbin, Shanghai, Shenyang, Beijing,
Xi’an, and Nanjing) from September-December 2005. Eli-
gible subjects were randomly and double-blindly assigned
to one of the three treatment groups: 1) enalapril tablet
(10 mg, control group); 2) enalapril-FA tablet (10 mg ena-
lapril combined with 0.4 mg of FA, low FA group); or 3)
enalapril-FA tablet (10 mg enalapril combined with 0.8 mg
of FA, high FA group), once daily for 8 weeks.
Demographic and clinical information were obtained
at baseline. Blood homocysteine concentrations were
examined at baseline and at 4 and 8 weeks of the trial.
MTHFR C677T and MTR A2756G genotypes were
determined for each study subject.
All analyses were performed according to the principle
of intention to treat. Homocysteine and folate concentra-
tions in the natural logarithms (due to their positively
skewed distributions) were analyzed as continuous vari-
ables. The relative change of homocysteine is expressed as
the change of homocysteine after FA treatment relative to
baseline concentration [(homocysteine after treatment-
homocysteine at baseline)/(homocysteine at baseline)],
which was applied as the primary outcome. Multivariable
regression models were applied to compare the relative
change of homocysteine among different groups. The
additive models were used to test the gene-gene interac-
tive effect between the MTHFR C677T and the MTR
A2756G polymorphisms on the homocysteine-lowering
efficacy of FA supplementation with and without adjust-
ments for the potential non-genetic confounding factors.
Statistical analysis was performed using SAS software ver-
sion 6.12 (SAS Institute, Cary, NC, USA).
Results
A total of 480 patients were recruited for this study. This
analysis excluded 35 subjects who were ineligible to parti-
cipate in the trial (7 in control group: 9 in low FA group; 8
in high FA group) or without data of MTHFR genotype (2
in high FA group) or MTR A2756G (1 in control group; 4
in low FA group; 4 in high FA group). Accordingly, a total
of 445 subjects were included in our final analysis.
The prevalence of MTHFR C677T polymorphisms 677
CC, 677 CT, and 677TT were 0.256, 0.497, and 0.247,
respectively. The prevalence of the 2756AA, 2756AG, and
2756 GG genotypes were 0.820, 0.171, and 0.009, respec-
tively. This population had no significant deviations in
genotype distributions from expected Hardy-Weinberg
equilibrium. Because there were only four subjects homo-
zygous for the G2756 allele, the genotypes AG and GG
were combined for statistical analyses.
Table 1 shows the baseline characteristics of the subjects
according to MTHFR and MTR genotypes. Subjects with
MTHFR 677 TT genotype had significantly higher homo-
cysteine concentrations (median: 17.5 μmol/L) than did
those with CT (11.5 μmol/L) or CC (11.1 μmol/L) geno-
type (P < 0.01 for either of these genotypes). However,
homocysteine concentrations did not differ among sub-
jects with different genotypes of the MTR gene. There was
no significant interactive effect between MTHFR C677T
and MTR A2756G polymorphisms on homocysteine con-
centrations at baseline.
Compared to baseline, after 4 or 8 weeks of FA treat-
ment decreases in plasma homocysteine concentrations
were seen across all MTHFR C677T genotypes and FA
dosage groups (Table 2). Even after the treatment,
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CT genotypes remained significantly higher at week 4 or
w e e k8( P < 0.05 for either of these genotypes) com-
pared to those with CC genotype in the low FA group.
In contrast, only subjects with TT genotype had higher
homocysteine concentrations compared to CC genotype
(P < 0.05) at week 4 or week 8 in the high FA group
(Table 2).
Furthermore, in the high FA group subjects with TT
genotype showed a significantly greater homocysteine-low-
ering response than did subjects with CC genotype at
w e e k4o rw e e k8 ,w i t ho rw i t h o u ta d j u s t m e n t sf o rt h e
relevant demographic and clinical characteristics at base-
line (mean percent reduction of homocysteine at week 4:
CC 5.9% vs. TT: 20.3%, P < 0.001; mean percent reduction
of homocysteine at week 8: CC 10.8% vs. TT: 22.0%, P =
0.005). This heightened level of response was not shown
in the low FA group (mean percent reduction of homocys-
teine at week 4: CC 8.8% vs. TT 10.6%, P = 0.769; mean
percent reduction of homocysteine at week 8: CC 9.9% vs.
TT 11.2%, P = 0.989) (Table 2).
T h ec h a n g ei nh o m o c y s t e i n ew a sp o s i t i v e l yr e l a t e dt o
the baseline homocysteine concentrations in all geno-
types and FA dosage groups. When baseline homocys-
teine also was adjusted, subjects with TT genotype
seemed to have an attenuated homocysteine lowering
response compared to subjects with CC genotype (P =
0 . 0 3 6a tw e e k4 ,P = 0.002 at week 8) in the low FA
group, but not in the high FA group (P =0 . 4 4 9a tw e e k
4, P = 0.414 at week 8). Our results did not substantially
alter with further adjustment for baseline folate concen-
tration and folate change after treatment.
Compared to baseline, after 4 or 8 weeks of FA treat-
ment, decreases in plasma homocysteine concentrations
were seen in all MTR A2756G genotypes and FA dosage
groups, except in subjects with AG/GG genotype in the
low FA group at week 4. However, neither the homocys-
teine concentration post-FA treatment nor the homo-
cysteine-lowering response of FA supplementation was
affected by MTR A2756G polymorphism (Table 3).
There was no significant interactive effect between
MTHFR C677T and MTR A2756G polymorphisms on
the homocysteine-lowering efficacy of different doses of
FA supplementation with or without adjustments for
potential non-genetic confounding factors.
We obtained similar results when we restricted our
analyses to subjects who fully complied with the protocol
(consuming at least 80% of all of the prescribed drugs)
during the treatment periods (per protocol set, n = 381)
(data not shown).
Discussion
Both a previous dose-finding trial [10] and a dose-
response trial [11] have discussed the relationship between
homocysteine-lowering efficacy and optimal dose of FA
supplementation, but without considering the possible
modifying effect of MTHFR C677T polymorphism. A
more recent study [12] evaluated the effect of MTHFR
C677T polymorphism on the response to different doses
of FA supplementation (0.1 mg/d, 0.4 mg/d, 4 mg/d and 4
mg/week) in northern Chinese women of childbearing age
and reported that the MTHFR 677 TT genotype was an
independent predictor of plasma homocysteine concentra-
tions, irrespective of FA dose, which was consistent with
our results. However, the study population consisted of
young women and the FA dosage category was not opti-
mal, being either too low (0.1 mg/d) or too high (4 mg/d).
Furthermore, plasma homocysteine concentrations
Table 1 Baseline characteristics of participants by MTHFR C677T or MTR A2756G polymorphism
1
MTHFR C677T MTR A2756G
All CC CT TT P AA AG/GG P
N 445 114 221 110 365 80
Sex(Male), no.(%) 191(42.9) 51(44.7) 91(41.2) 49(44.5) 0.761 155(42.5) 36(45.0) 0.678
Age, yrs 57.0(9.8) 57.0(9.5) 56.4(9.6) 58.2(10.4) 0.284 57.0(9.8) 57.0(9.9) 0.971
BMI, kg/m
2 25.7(3.5) 25.5(3.9) 25.8(3.3) 25.7(3.3) 0.758 25.8(3.5) 25.2(3.5) 0.137
SBP, mmHg 154.0(11.2) 154.0(11.5) 153.8(11.4) 154.5(10.5) 0.863 153.8(11.2) 155.1(11.2) 0.324
DBP, mmHg 93.0(8.3) 92.4(8.5) 93.4(7.8) 92.8(9.0) 0.530 93.3(8.0) 91.4(9.4) 0.052
FPG, mmol/L 5.5(1.3) 5.5(1.5) 5.4(1.2) 5.7(1.2) 0.312 5.5(1.3) 5.5(1.2) 0.865
TC, mmol/L 5.0(1.1) 5.0(1.4) 4.9(1.0) 5.1(1.0) 0.555 5.0(1.1) 4.9(1.1) 0.259
HDL-C, mmol/L 1.3(0.4) 1.3(0.4) 1.3(0.4) 1.3(0.4) 0.479 1.3(0.4) 1.3(0.3) 0.542
TG, mmol/L 1.7(1.2) 1.7(1.0) 1.8(1.2) 1.7(1.5) 0.970 1.8(1.3) 1.6(0.8) 0.252
Creatinine, μmol/L 69.5(17.5) 68.0(17.5) 69.2(17.3) 71.9(17.9) 0.233 69.2(17.9) 71.3(15.6) 0.334
Folate, nmol/L
2 12.6(1.5)[12.3] 13.7(1.4)[13.4] 13.0(1.5)[12.6] 11.0(1.4)[10.8] * < 0.001 12.8(1.5)[12.5] 11.9(1.5)[11.6] 0.107
Homocysteine, μmol/L
2 13.2(1.6)[12.1] 11.2(1.4)[11.1] 12.0(1.4)[11.5] 18.8 (1.8)[17.5] * < 0.001 13.1(1.6)[12.1] 13.3(1.6)[12.6] 0.794
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, FPG = fasting plasma glucose,
TC = total cholesterol, HDL-C = high-density lipoprotein cholesterol, TG = triglyceride;
1Means (SD);
2geometric mean (anti-log SD), median in brackets; * Significantly different from the CT or CC genotype, P < 0.001.
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tion) were lower than those observed in a U.S. population
[13] and a Chinese population [14], which means that this
Chinese population was not a representative population in
which to evaluate the homocysteine lowering effect of FA.
In our study, we investigated if the change in plasma
homocysteine concentration in response to two commonly
used physiological doses (0.4 mg/d and 0.8 mg/d) of FA
supplementation could be modified by individual MTHFR
C677T and MTG A2756G polymorphisms in a multicen-
ter, randomized, double-blind, controlled trial in hyperten-
sive Chinese adults, whose homocysteine concentrations
were comparable to the general Chinese population [14].
Consistent with a previous study [15], baseline homocys-
teine concentration was the major determinant of the
homocysteine-lowering effect in all genotypes and FA
dosage groups. Subsequently, in the present study, after 4
or 8 weeks of treatment, subjects with MTHFR 677 TT
genotype had a significantly greater homocysteine-lower-
ing response than did subjects with CC genotype in the
high FA group. However, such a heightened response was
not shown in the low FA group. Furthermore, when we
further adjusted baseline homocysteine, subjects with TT
genotype seemed to have a more attenuated homocys-
teine-lowering response than did subjects with CC geno-
type in the low FA group but not in the high FA group.
The molecular mechanisms that underlie clinical remedia-
tion of enzyme variants are the ability of elevated levels of
the cofactor or substrate to overcome the binding defects
of Km mutants or to serve as a chemical chaperone to
Table 2 Response of plasma homocysteine to different doses and duration of folic acid supplementation by MTHFR
C677T genotypes
N Homocysteine, μmol/L
1
Percent relative change of homocysteine
2
Difference in change of
Homocysteine at 4 weeks by
genotypes
3
Difference in change of
Homocysteine at 8 weeks by
genotypes
3
baseline 4 weeks 8 weeks b SE P b SE P
Control
CC 41 11.6(1.4)[11.3] 11.9(1.3)[11.8] 11.8(1.4)[11.3]
3.35(13.7) 2.2(14.0) ref ref .
CT 73 11.0(1.4)[11.1] 11.2(1.4)[11.3] 11.3(1.4)[11.1]
2.25(13.2) 3.1(14.0) -3.69 2.94 0.209 -1.80 3.45 0.601
TT 38 18.1(1.9)[14.7]
# 18.0(1.9)[15.6]
# 18.1(1.8)[16.5]
#
1.19(19.7) 3.3(27.0) -4.05 3.33 0.225 -0.52 3.91 0.895
Total 152 12.7(1.6)[12.0] 12.8(1.6)[11.7] 12.8(1.6)[12.0]
2.3(15.1) 2.9(18.0)
Low FA
CC 34 11.0(1.3)[11.0] 9.9(1.3)[9.4]* 9.8(1.3)[9.5] *
-8.8(13.0) -9.9(14.9) ref ref
CT 79 12.6(1.5)[11.4] 11.5(1.4)[11.1] *
# 11.2(1.4)[10.7] *
#$
-7.6(15.4) -9.7(16.8) 2.14 3.35 0.523 2.52 3.88 0.516
TT 34 17.5(1.8)[17.2]
# 15.2(1.7)[14.2] *
# 14.8(1.6)[14.2] *
#
-10.6(21.3) -11.2(27.1) -1.16 3.95 0.769 0.06 4.58 0.989
Total 147 13.2(1.6)[11.6] 11.8(1.5)[11.3] * 11.6(1.5)[10.8] *
$%
-8.6(16.4)
% -10.1(19.1)
%
High FA
CC 39 11.0(1.4)[10.8] 10.2(1.4)[10.1] * 9.7(1.4)[9.8] *
$
-5.9(14.2) -10.8(11.1) ref ref
CT 69 12.3(1.3)[12.0] 10.8(1.3)[11.0] * 10.7(1.3)[10.5] *
-11.2(14.5) -11.2(16.5) -6.21 3.19 0.052 -0.47 3.39 0.890
TT 38 20.8(1.8)[19.6]
# 15.8(1.6)[14.2] *
# 15.4(1.6)[14.1] *
#
-20.3(22.2)
# -22.0(23.8)
# -15.51 3.72 < 0.001 -11.12 3.95 0.005
Total 146 13.7(1.6)[12.7] 11.7(1.5)[11.4] * 11.5(1.5)[10.8] *
%
-12.1(17.5)
% -13.9(18.1)
%
1Geometric mean (anti-log SD), median in brackets;
2[(Homocysteine after treatment - homocysteine at baseline)/(homocysteine at baseline)]*100, Mean(SD);
3Regression model was adjusted for age, sex, BMI, baseline SBP, DBP, creatinine, TG, HDL-C, TC, FPG, folate, folate change, MTR A2756G polymorphism and study
centers;
*Significantly different from baseline, P < 0.05;
$Significantly different from week 4, P < 0.05;
#Significantly different from the CC genotype, P < 0.05;
%Significantly different from control group, P < 0.05.
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Our results further suggest that daily 0.4 mg FA supple-
mentation may be insufficient, and that a daily dose of 0.8
mg FA may be required to lower homocysteine concentra-
tion in subjects with TT genotype.
Furthermore, after the treatment, subjects with CT gen-
otype had significantly higher homocysteine concentra-
tions than those with CC genotype in the low FA group,
and had similar homocysteine concentrations as CC sub-
jects in the high FA group. These results indicate that
daily 0.8 mg FA also may be necessary for lowering homo-
cysteine concentration in subjects with CT genotypes.
However, although they showed a greater homocysteine
lowering effect than subjects with CC genotype, subjects
with TT genotype still had the highest homocysteine con-
centrations even after 8 weeks of high FA treatment.
Therefore, other therapeutic strategies need to be devel-
oped to reduce the risk associated with hyperhomocystei-
nemia in TT subjects.
In fact, Malinow et al. [18] first reported that TT subjects
experienced much greater decreases in plasma total homo-
cysteine concentrations after receiving FA at a dose of 1 or
2 mg/d for 3 weeks than did CC subjects. Among subjects
who were not previously taking multivitamins, the mean
reductions in plasma total homocysteine concentrations
were -20.9%, -13.1%, and -7.1% in persons with the TT,
CT, and CC genotypes, respectively (P = 0.019 for TT ver-
sus CC). A similar result also has been reported in a study
in Taiwan, in which 5 mg of FA daily were supplemented
for 8 wks [19]. Our results appear to be consistent with
these studies. However, the study of Woodside et al. [20]
showed that TT subjects are less responsive to the effects
of FA and B-vitamin supplementation (daily 1 mg FA, 7.2
mg Vitamin B6, and 0.02 mg Vitamin B12 for 8 wks.) than
CC subjects. And Ho GY et al. [21] also reported that
MTHFR C677T did not impact the total homocysteine-
lowering effect of vitamins (daily 2.5 mg FA, 25 mg Vita-
min B6, and 0.5 mg Vitamin B12 for 1 year) in a study per-
formed in Singapore. The reasons for the disparities
among the results of these studies are unknown. Additional
large dose-finding studies are required to further elucidate
the possible contributory factors, such as folate status, eth-
nicity of the participants, and in particular the possible
effects of concomitant vitamin B6 and/or B12.
Table 3 Response of plasma Homocysteine to different doses and duration of folic acid supplementation by MTR
A2756G genotypes
N Homocysteine, μmol/L
1
Percent relative change of homocysteine
2
Difference in change of
Homocysteine at 4 weeks by
genotypes
3
Difference in change of
Homocysteine at 8 weeks by
genotypes
3
baseline 4 weeks 8 weeks b SE P b SE P
Control
AA 130 12.8(1.6)[12.0] 12.9(1.6)[11.7] 12.9(1.6)[12.0]
1.7(15.1) 2.33(17.7) ref ref .
AG/GG 22 12.1(1.5)[11.7] 12.6(6.8)[1.6] 12.6(1.5)[12.2]
5.8(15.2) 6.32(20.1) 5.17 3.50 0.139 6.08 4.10 0.138
Total 152 12.7(1.6)[12.0] 12.8(1.6)[11.7] 12.8(1.6)[12.0]
2.3(15.1) 2.9(18.0)
Low FA
AA 116 12.9(1.6)[11.5] 11.5(1.5)[11.1]* 11.3(1.5)[10.6] *
-9.4(16.5) -10.2(19.4) ref ref
AG/GG 31 14.1(1.5)[14.5] 13.1(1.5)[12.3] 12.5(1.5)[12.3] *
$
-5.4 (15.9) -9.6(18.3) 3.73 3.33 0.262 -0.06 3.86 0.989
Total 147 13.2(1.6)[11.6] 11.8(1.5)[11.3] * 11.6(1.5)[10.8] *
$%
-8.6(16.4)
% -10.1(19.1)
%
High FA
AA 119 13.7(1.6)[12.7] 11.8(1.5)[11.4] * 11.5(1.4)[10.8] *
$
-12.3(16.2) -14.4(17.3) ref ref
AG/GG 27 13.5(1.8)[12.9] 11.6(1.5)[11.4] * 11.5(1.5)[10.7] *
-11.5(22.7) -11.9(21.5) 1.30 3.39 0.700 2.72 3.60 0.450
Total 146 13.7(1.6)[12.7] 11.7(1.5)[11.4] * 11.5(1.5)[10.8] *
%
-12.1(17.5)
% -13.9(18.1)
%
1Geometric mean (anti-log SD), median in brackets;
2[(Homocysteine after treatment - homocysteine at baseline)/( homocysteine at baseline)]*100, Mean(SD);
3Regression model was adjusted for age, sex, BMI, baseline SBP, DBP, creatinine, TG, HDL, TC, FPG, MTHFR C677T polymorphism and study centers;
*Significantly different from baseline, P < 0.05;
$Significantly different from week 4, P < 0.05;
%Significantly different from control group, P < 0.05.
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tration at baseline or post-FA treatment nor the homo-
cysteine lowering response of FA supplementation was
affected by MTR A2756G polymorphism. However,
there was a significant homocysteine reduction in MTR
2756 AG/GG genotype after 4 weeks of FA supplemen-
tation in the high FA (0.8 mg/d) group, but not in the
low FA (0.4 mg/d) group, which means that we cannot
exclude the possible role of MTR A2756G polymorph-
ism in the homocysteine metabolic pathway.
Overall, our results suggest that daily 0.8 mg FA may be
necessary to lower homocysteine concentration for Chi-
nese hypertensive subjects with CT or TT genotype,
which have important clinical and public health implica-
tions. Increased homocysteine concentration has been
implicated as a risk factor for neural tube defects (NTDs)
and Downs syndrome [22,23]. A study by Wilcken et al.
reported that the frequency of CT and TT genotypes in
Hungary was about 45% and 11.1%, respectively [24]. Two
Hungarian intervention trials [25,26], which used a multi-
vitamin containing 0.8 mg folic acid, found a significant
reduction in the first occurrence of urinary tract and car-
diovascular abnormalities beyond the 90% reduction of
NTDs. There is no evidence that 0.4 mg folic acid has a
similar preventive effect on defects beyond NTDs. Our
results further suggest that there may be an additional
benefit if a daily dose of 0.8 mg, but not 0.4 mg, of folic
acid could be used in women, particularly in populations
with a high frequency of T allele (such as the Chinese) and
without folic acid fortification. Furthermore, identifying
TT or CT subjects and providing them with an optimal
dose of folic acid also may be very important in the pre-
vention of CVD [4,27] in populations without folic acid
fortification.
Our study has the following strengths. This was a rando-
mized, multicenter and double blind trial. This study
simultaneously assessed the effect of FA dosages and gene
polymorphisms on homocysteine-lowering efficacy. Our
trial studied two commonly used doses of FA, which are
of important clinical and public health relevance. How-
ever, caution is needed in generalizing our findings from
this hypertensive Chinese population to other populations.
Furthermore, though similar results were obtained when
we restricted our analyses to subjects who fully complied
with the protocol during the treatment periods, we still
could not fully exclude the effect of non-compliance pro-
blem on our results. Also, it should be noted that we did
not measure other polymorphisms in the folate pathway,
such as the MTHFR A1298C variant. Furthermore, the
treatment period with FA was only 8 weeks and the sam-
ple size was rather small when sub-grouped into various
groups (control, low FA and high FA) for genetic associa-
tion studies. Future studies with longer treatment duration
and a larger sample size are needed to confirm our results.
The association between angiotensin-converting enzyme
inhibitor treatment and the change of homocysteine was
controversial [28,29]. We did not observe a significant
relationship between enalapril treatment and homocys-
teine change in our study.. Additional large sample studies
also are needed to further examine the relationship of ena-
lapril treatment with homocysteine change and the possi-
ble interactive effects between enalapril and folic acid on
the change in homocysteine.
Conclusions
We demonstrated that MTHFR C677T polymorphisms
can not only affect plasma homocysteine levels at base-
line and post-FA treatment, but also modify therapeutic
response to various dosages of FA supplementation.
These findings, if confirmed by additional studies, may
enable medical providers to offer more personalized
care and advice on FA supplementation for a given
individual.
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